Aggregate Asset Value: Organon & Co (OGN)

Corporate emblem and logo of Organon & Co (OGN)

Organon & Co. (OGN) demonstrates a financial base formed by wholesale supplies of contraceptives and biosimilars to global clinics, with the indicator value reaching 13312.10. Stable management has successfully adapted the structure following the business spin-off, focusing on portfolio expansion. The technology stack is augmented by AI platforms and robotic lines, reducing manual labor costs and defect rates.

OGN: organon.com Aggregate Company Assets 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Organon Corp (OGN)

- price and consensus price forecast:
Quote Chart organon.com|OGN - Analyst Consensus Forecast
- market capitalization data:
Market Value Organon Pharma|OGN - Enterprise Value
- book capitalization data:
Book Value per Share Organon|OGN - Company Book Value|Market Value to Book Value organon.com|OGN - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Organon & Co.|OGN - Long-Term Debt to Capital|Short-Term Debt to Capital Organon Pharma|OGN - Company Total Debt|Debt to Net Assets Ratio Organon Pharma|OGN - Company Long-Term Liabilities|Company Current Liabilities Organon
Analysis of all company metrics:OGN, organon.com
Manufactured product of Organon Corp

Total assets determine the aggregate volume of the firm's resources and liabilities, while a reverse calculation via ROA allows for real-time tracking of balance sheet dynamics. By analyzing asset trends through ROA, an investor assesses the stability of the Organon & Co. (OGN) base against a backdrop of high debt leverage and the risks of losing patent protection for key women's health drugs.

Key competitors

darebioscience.com (DARE) - Total Asset Value of Company|TXMD - Company Total Assets|Aggregate Asset Value Palatin Technologies Inc